MA-VERISTAT
29.3.2022 16:09:09 CEST | Business Wire | Press release
Veristat , a scientific-minded global clinical research organization (CRO), announced today the formalization of its Strategic Resourcing solution to offer clients the delivery of clinical development and regulatory expertise options fully tailored to their needs. Clients now have access to difficult-to-find experts dedicated to a specific requirement or function to meet their objectives and timelines.
Veristat has been providing demand-based resourcing on a less formalized basis for many years. With the Strategic Resourcing solution, a pipeline of discipline-specific expertise is available and ready to seamlessly integrate into dynamic clinical environments. Veristat resources support work across many disciplines including biostatistics, programming and data management, regulatory consulting, clinical operations including clinical monitoring, project management, site management, as well as medical affairs/safety, medical/regulatory writing, and pharmacovigilance.
“The biopharmaceutical industry is innovating and developing new treatments so rapidly that resourcing demands now outpace the current available talent pool,” commented Patrick Flanagan, Chief Executive Officer at Veristat. “This was a top industry challenge prior to the COVID-19 pandemic, and it remains a top challenge today. Sponsors expect their external partners to continually improve upon the ways in which they can help them achieve true scientific progress delivered with process agility. Our strategic resourcing option provides the necessary flexibility to support a client project in the manner they determine is best.”
Leading the initiative is Bill Donovan, Senior Vice President, Strategic Solutions at Veristat. An industry veteran, Bill has 20+ years of leadership experience partnering with global pharmaceutical and biotechnology companies to accelerate time-to-market results across all stages of clinical trials. Delivering quality specialty resourcing to meet a sponsor’s full spectrum of needs has been a vital component of customer engagements led by Donovan.
“Refining the ways in which we partner with clients to deliver higher efficiencies with accelerated timelines is an ongoing focus for us,” commented Donovan. “Providing drug developers with an agile and specialized resourcing model fully supports this objective. I am thrilled that Veristat has formalized our ability to enhance customer value by allowing sponsors to hire our experts when they cannot find the right talent to support study success.”
Veristat is currently working on projects to treat cancers, rare diseases, neurological disorders, infectious diseases and more. Treatments span vaccines, gene therapies, complex generics, immuno-therapies, and novel drugs. For many clients, Veristat becomes a sponsor’s project team. For others, Veristat provides the medical, scientific, clinical, and statistical expertise to help sponsors advance their therapy into and through the clinical development and regulatory approval process.
Veristat continues to offer its core end-to-end capabilities across the development continuum in both full service and functional service support capabilities as well. Learn more about Veristat’s Strategic Resourcing Solutions here: https://www.veristat.com/services/strategic-resourcing
About Veristat
Veristat , a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 27 years’ experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared nearly 100 marketing applications for approval with global regulatory authorities in the last 10 years.
Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the most complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives. Our bold thinking, focus, and extensive experience supporting complex drug development in rare and ultra-rare diseases significantly impacted the approval of 12% of the 2021 U.S. Food and Drug Administration (FDA) novel drugs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220329005174/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release
Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co
EdgeConneX Looks to Enter Swedish Market as Part of European Data Center Expansion Strategy27.2.2026 08:05:00 CET | Press release
Planned data center campus in Skellefteå would support future AI and cloud infrastructure needs EdgeConneX®, an EQT portfolio company with an extensive Pan-European data center footprint, looks to expand its presence with a new site located in Skellefteå, Sweden. The data center site will be acquired from Lyten, a global company that specializes in lithium-sulfur batteries and energy storage. The site would support EdgeConneX broader strategy to expand digital infrastructure capacity across the Nordics. Subject to the completion of applicable administrative and regulatory processes, EdgeConneX will look to develop a data center campus with potential capacity of up to one gigawatt in support of future AI and cloud computing workloads. Upon completion, the data center campus would be one of the largest facilities in Europe that would be primarily powered by renewable energy. “Sweden represents an attractive long‑term market for digital infrastructure investment. The country’s access to r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom